Wanbury recently received a No DMF deficiency letter from the US Food and Drug Administration (USFDA) for multiple Abbreviated New Drug Applications (ANDAs) with Metformin HCl API source of Wanbury for different formulations. According to reports from Business Standard, this regulatory approval represents a significant milestone for the company's US market expansion efforts. The disclosure was made under Regulation 30 of SEBI LODR on Thursday, with the company informing exchanges about this clean regulatory status. Shares of Wanbury traded at ₹308.75 on the NSE following the announcement.
A No DMF deficiency letter means the USFDA reviewed the drug master file covering Wanbury's metformin HCl active pharmaceutical ingredient and raised no deficiencies against it. For an API maker, this is a clean regulatory signal that removes potential roadblocks for finished dosage makers who rely on Wanbury as their metformin source. Since the letter covers multiple ANDAs tied to Wanbury as the API supplier, several formulation customers can advance their US filings without supply-side regulatory hurdles, strengthening Wanbury's positioning as a validated metformin API vendor into the US market.
Wanbury has expanded business opportunities in South Korea by filing the DMF for one more API, as reported by Business Standard. This filing demonstrates the company's strategic focus on diversifying its global API supply portfolio and establishing a stronger presence in the South Korean pharmaceutical market. The South Korea DMF filing adds a second regulated market to the expansion, pointing to a strategy of widening the geographic base for its API portfolio beyond the US.
According to Business Standard, Wanbury is committed for supply of best APIs to the new market for the well-being of human beings. The company's approach emphasizes quality and reliability in its API supply chain, positioning itself as a trusted partner for pharmaceutical manufacturers seeking high-quality active pharmaceutical ingredients for various formulations. Metformin, the world's most widely prescribed oral diabetes drug, sits in a high volume low margin API segment where regulatory reliability and cost competitiveness decide who wins market share. A clean USFDA read on the DMF is a commercially relevant credential rather than a routine compliance note, supporting order visibility for Wanbury's metformin API franchise in the quarters ahead.
